Reblozyl

Chemical Nameluspatercept–aamt
Dosage FormInjection (subcutaneous; 25 mg/vial, 75 mg/vial)
Drug ClassMiscellaneous
SystemBlood
CompanyCelgene Corporation
Approval Year2019

Indication

  • Reblozyl is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?